Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Neutral 49.6%

Neg 0% Neu 49.6% Pos 0%

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.

Comments

No comments yet. Be the first!